When analyzing FDA Complete Response Letters issued between 2020 and 2024, one trend becomes immediately clear: Chemistry, Manufacturing, and Controls (CMC) issues continue to be among the most common reasons programs encounter regulatory setbacks. Inadequate stability data, poorly developed analytical methods, process validation deficiencies, and insufficient oversight of manufacturing activities routinely result in agency questions, delays, and additional development costs.
The encouraging reality is that many of these issues are entirely preventable. In our experience, early-stage companies often face competing priorities. Teams are under pressure to meet investor expectations, conserve capital, and advance programs toward the clinic as quickly as possible. As a result, critical CMC activities may not always receive the level of planning and attention they require. Whether development activities are performed internally or outsourced to external partners, a strong CMC package does not happen by accident. It is built intentionally through scientific understanding, thoughtful planning, and regulatory foresight.
So what separates a strong CMC package from one that creates unnecessary risk?
Start CMC Planning Early
The strongest CMC packages start early and are built over time.
Development teams that wait until IND-enabling activities are underway often discover critical gaps in formulation knowledge, analytical methods, stability data, or manufacturing readiness. These deficiencies rarely appear at convenient times.
Early planning allows teams to:
- Identify critical studies before they become urgent.
- Align development activities with regulatory expectations.
- Anticipate manufacturing challenges.
- Reduce the likelihood of repeating work later.
The programs that move efficiently into the clinic are often the ones that invested in CMC strategy from the beginning.
Develop a Thorough Understanding of the Product
Regulators expect sponsors to fully understand their product.
This includes:
- Physical and chemical properties of the API.
- Formulation characteristics.
- Critical quality attributes.
- Degradation pathways.
- Compatibility considerations.
- Process parameters that influence product quality.
A strong CMC package tells the story of the product and demonstrates that decisions were made based on scientific understanding rather than assumptions.
Build Analytical Methods That Support Development
Robust analytical methods are frequently viewed as a late-stage requirement, but they are essential throughout development.
Having stage appropriate analytical methods support:
- Formulation development decisions.
- Stability assessments.
- Manufacturing investigations.
- Specification development.
- Regulatory submissions.
Methods that are poorly developed or inadequately qualified can create significant delays when additional data are required.
Generate Meaningful Stability Data
Stability studies are often initiated simply to satisfy a regulatory expectation.
However, stability data provide critical insight into:
- Product shelf life.
- Storage conditions.
- Packaging suitability.
- Degradation mechanisms.
- Potential formulation risks.
A well-designed stability program helps identify issues early, allowing teams to make informed decisions before entering clinical studies.
Consider Manufacturing Early
Many development programs encounter delays because manufacturing considerations were introduced too late.
Questions that should be addressed early include:
- Can the formulation be scaled successfully?
- Are the selected excipients commercially available?
- Is the manufacturing process reproducible?
- Can a contract manufacturer execute the process?
- Are there supply chain risks?
Development decisions made in the laboratory can have substantial implications during technology transfer and GMP manufacturing.
Incorporate Regulatory Thinking Throughout Development
Strong CMC packages are built with the regulatory review process in mind.
Every study, development activity, and manufacturing decision should contribute to answering fundamental questions:
- Is the product adequately characterized?
- Can it be consistently manufactured?
- Are appropriate controls in place?
- Is the product suitable for clinical use?
Regulatory deficiencies often arise not because data are missing, but because the overall development story lacks clarity.
CMC is not a Checkbox
Investors may focus on clinical milestones, and development teams often prioritize speed. But CMC remains one of the most common causes of unexpected delays, additional costs, and regulatory questions.
The strongest programs recognize that CMC is not simply documentation prepared before an IND submission. It is the scientific foundation that supports the entire development program.
Teams that invest early in thoughtful CMC planning frequently reach clinical milestones faster, avoid costly rework, and enter regulatory interactions with greater confidence.
A strong CMC package does not happen at the end of development. It is built throughout the entire journey.
Whether you’re preparing for your first IND, troubleshooting a stalled program, or approaching an NDA, CMC Pharma is offering a complimentary 30-minute discussion to talk through your program.
Not ready for a call? Follow CMC Pharma on LinkedIn for weekly CMC insights, practical guides, and reference content that is built for developers, investors, and program stakeholders at every stage.